FAU.de
Deutsch
Login
Home
Publications
Research Grants
Inventions & Patents
Awards
Additional Research Activities
Faculties & Institutions
Research Areas
Lehrstuhl für Experimentelle Medizin mit dem Schwerpunkt Molekulare Pathogeneseforschung
Friedrich-Alexander-Universität Erlangen-Nürnberg
Medizinische Fakultät
Einrichtungen, die nicht zum Universitätsklinikum Erlangen gehören
Klinisch-Molekularbiologisches Forschungszentrum
Overview
Publications
(128)
Research Grants
(16)
Project Types
Toggle all
Third Party Funds Group - Overall project
Third Party Funds Group - Overall project
Third Party Funds Group - Sub project
Third Party Funds Group - Sub project
Third party funded individual grant
Third party funded individual grant
Internally funded project
Internally funded project
FAU own research funding: EFI / IZKF / EAM ...
FAU own research funding: EFI / IZKF / EAM ...
Non-FAU Project
Non-FAU Project
Status
All
Upcoming
Ongoing
Finished
Project year
From
To
Filters (inactive)
Targeting the roots of cancer metastasis and therapy resistance (BR 1399/17-1)
July 1, 2023 - June 30, 2028
Kinase signaling in the immune responses of small-cell lung cancer
April 1, 2024 - April 1, 2027
Cancer cell colonization of the lung epithelium
Sept. 1, 2023 - Sept. 1, 2026
Immune escape mechanisms in lung cancer
April 1, 2023 - April 1, 2026
Mechanisms of metastasis in lung cancer
April 1, 2023 - April 1, 2026
The role of the EMT-transcription factor Zeb1 in CAFs for metastatic colonisation and growth (B07) (SFB/TRR 305 B07)
TRR 305: Über die Analyse der metastatischen Koloniebildung zu neuen systemischen Krebstherapien
Jan. 1, 2021 - Dec. 31, 2024
Metabolische Dysregulationen bei EMT-getriebener metastatischer Kolonisierung (A03) (SFB/TRR 305 A03)
TRR 305: Über die Analyse der metastatischen Koloniebildung zu neuen systemischen Krebstherapien
Jan. 1, 2021 - Dec. 31, 2024
Deciphering LIN28B as a biomarker in squamous cell lung carcinomas for treatment with PD-1/PD-L1 signaling blockade and evaluating combined anti-VEGFR2 with PD-1/PD-L1 signaling lockade as a novel therapy option
Dec. 1, 2021 - Nov. 30, 2024
P133-OA: Combined targeting of chemoresistant cancer cells and immune-suppressive CAFs for cancer therapy
Jan. 1, 2024 - Sept. 30, 2024
Zeb1-vermittelte Kontrolle des PUFA/MUFA-Verhältnisses in der EMT-assoziierten Ferroptose-Sensitivität
Aug. 1, 2021 - July 31, 2024
‹
1
2
›